Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotec...
NEW YORK/LOS ANGELES - Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.
Aimovig, which won U.S. and European approvals last year, belongs to a new class of medicines that also includes Eli Lilly and Co’s Emgality and Teva Pharmaceutical Industries Ltd’s Ajovy. Amgen, in an emailed statement, said it is seeking to terminate the collaboration agreements with Novartis and obtain damages, but termination would not be effective until the litigation is resolved.
“The program about which Amgen has complained is being terminated,” Novartis said, and the lack of a breach means Amgen’s April 2 notice terminating the collaboration agreements should be deemed void. The lawsuit seeks to enforce the companies’ collaboration agreements and declare Amgen’s purported termination void.
FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013. REUTERS/Robert Galbraith/Files/File Photo
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Novartis sues Amgen over collaboration on migraine treatment AimovigSwiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotec...
Lire la suite »
Novartis sues Amgen over migraine treatment AimovigSwiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotec...
Lire la suite »
2 drug giants are feuding over a highly successful new migraine drug, and court documents reveal how profitable the $10 billion market could beTwo drugmakers, Amgen and Novartis, have worked together for years on a new type of cutting-edge migraine drug, Aimovig.
Lire la suite »
Novartis sues Amgen over migraine treatment AimovigSwiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotec...
Lire la suite »
Novartis sues Amgen over collaboration on migraine treatment AimovigSwiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotec...
Lire la suite »
Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. groupBiogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and...
Lire la suite »
2 drug giants are feuding over a highly successful new migraine drug, and court documents reveal how profitable the $10 billion market could beTwo drugmakers, Amgen and Novartis, have worked together for years on a new type of cutting-edge migraine drug, Aimovig.
Lire la suite »